Guide

VICH Harmonisation: A Practical Readiness Guide for Multi-Region Veterinary Submissions

VICH — the International Cooperation on Harmonisation of Technical Requirements for Veterinary Medicinal Products — sits between the EU EMA-CVMP, US FDA-CVM, Japan MAFF/MHLW, and observer regions (Canada, Australia/New Zealand, South Africa) to harmonise technical guidelines for veterinary medicinal products. The VICH GL series covers stability (GL2), GCP (GL9), pharmacovigilance (GL24/GL29/GL30/GL35/GL42), bioequivalence (GL52), residue methods (GL49), and many more. A multi-region veterinary sponsor that ignores VICH duplicates work and arrives at inconsistent dossiers; a sponsor that runs VICH-aligned dossiers reduces submission burden materially. This guide walks the integrated VICH framework, the recurring multi-region findings, and a practical path to a defensible international submission strategy.

Start free trial Free trial, no credit card, onboard in days, not months.

What VICH harmonises and what it doesn't

VICH harmonises the technical content — what data must be generated, how studies are designed, how methods are validated. It does not harmonise the administrative submission — each region keeps its own dossier format (FDA-CVM NADA, EMA CVMP MAA, Japan animal drug application), its own fees, its own review timelines, and its own post-market obligations. A VICH-aligned technical package can be cut into each region's administrative wrapper without re-running studies — that is the actual harmonisation benefit. Sponsors who expect a single global submission are disappointed; sponsors who expect a single technical evidence base across regions are well served.

Stability (GL2/GL3/GL4/GL5) and the multi-region storage horizon

GL2 (stability testing of new veterinary drug substances and products) and the related GL3/GL4/GL5 set the harmonised stability design — climatic zones, study durations, container closure considerations. A study designed to GL2 with the right climatic-zone coverage satisfies EU, US and Japan; a study designed to a single region's prior guidance typically requires bridging data for the others. The cost differential is significant — VICH-designed stability is materially cheaper than parallel regional designs.

GCP (GL9) and the recurring clinical study findings

VICH GL9 sets Good Clinical Practice for veterinary clinical studies — ethics, target animal welfare, informed owner consent (companion animal), study design, data integrity. Inspection findings against GL9 typically cluster on three issues: incomplete informed-owner consent documentation, source-data integrity gaps between study record and case report form, and adverse event capture that does not link to the protocol's safety definitions. A GL9-aligned study should satisfy EMA, FDA-CVM and MAFF inspection on the technical conduct.

Pharmacovigilance: GL24/29/30/35/42 and the multi-agency PSUR/PSMF

VICH GL24 (PSUR), GL29 (PSMF), GL30 (signal management), GL35 (electronic submission) and GL42 (data elements for adverse event reports) harmonise the technical content of veterinary pharmacovigilance. Each region still operates its own pharmacovigilance system (EU EudraVigilance Veterinary; US FDA-CVM Form 1932; Japan MAFF system), but the underlying data elements, signal logic and PSUR content are harmonised. The recurring multi-region finding is a sponsor running region-specific PV teams with non-reconciled case files — the case is the same animal, the report differs.

MUMS, residue methods and the orphan pathway

GL49 sets the harmonised analytical method validation expectations for residue testing in food-producing species. The MUMS (Minor Use Minor Species) pathway at FDA-CVM and the analogous EU limited-market pathway provide accelerated submission routes for small-population indications — different in details across regions but with VICH-aligned technical content. Sponsors targeting MUMS routes in multiple regions benefit substantially from a VICH-aligned technical package.

Standards covered in this guide

Each standard, retailer code or assurance scheme referenced above has its own deep-dive page with scope, audit detail and common pitfalls.

Where this lives in V5 Ultimate

The clauses above aren't theoretical — every one maps to a shipped module and an industry profile. Jump to the parts of the product that turn this guide into evidence on a Monday morning.

Modules that do the work

VICH-aligned QMS

One technical evidence base, regional wrappers.

Harmonised PV intake

GL42 data elements once, dispatched per agency.

Multi-region PSUR

GL24-aligned PSUR feeds each region.

Industries this hits hardest

Veterinary pharma

Frequently asked

Is VICH adoption mandatory?

VICH guidelines are not legally binding in themselves — they are adopted into regional regulation by each member's competent authority. In practice, EMA, FDA-CVM and MAFF have adopted the VICH series substantively, so a VICH-aligned package is the operational standard for multi-region work.

Does VICH apply to biologics as well as small molecules?

VICH covers veterinary medicinal products broadly. Some guidelines (e.g. GL2 stability) apply more naturally to small molecules; biologics-specific harmonisation is patchier and often relies on WOAH (Terrestrial Manual) chapters alongside VICH.

What is the relationship between VICH and ICH?

VICH is the veterinary parallel to human pharma ICH. The two organisations coordinate where appropriate (e.g. GMP fundamentals) but VICH guidelines reflect the veterinary-specific considerations — multiple species, food-producing animals, residue concerns — that human ICH does not address.

If we file under one region's pathway, can we reference VICH guidance?

Yes — and you should. Regional regulators expect VICH-aligned content even on single-region submissions because their own guidance largely IS the VICH guidance. Citing VICH explicitly reduces deficiency-letter risk on the technical sections.

See it on your shop floor.

Free trial, no credit card, onboard in days, not months.

Start free trial See pricing →Browse all resources →